Scientists test Direct-to-Brain immune attack on deadly cancer
NCT ID NCT05474378
Summary
This early-stage trial is testing the safety and feasibility of a new personalized cell therapy for adults with recurrent glioblastoma, a very aggressive brain cancer. Doctors will collect a patient's own immune cells, genetically modify them to target a protein (B7-H3) found on cancer cells, and then infuse them directly into the brain after surgery. The main goals are to see if the cells can be reliably manufactured and to find a safe dose, while also checking for any early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN AND NERVOUS SYSTEM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford Cancer Institute
RECRUITINGPalo Alto, California, 94305, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.